(Ra)-2’s mutant selectivity over WT-EGFRcompares favorably to that of osimertinib, the standard of care formutant EGFR cancers, particularly for the L858R/T790M/C797S mutantwhich has proven to be a challenge to the drug.47 The gene discussed is EGFR; the disease is cancer.